A Phase 3 randomized, double-blind, 52-week (placebo-controlled for 36 weeks with a 16-week extension period), multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib (PF-06651600) in adult and adolescent participants with non-segmental vitiligo (both participants with active and no more than 50% of participants
with stable vitiligo).